Active, not recruitingPhase 2NCT04489771
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Studying Hereditary clear cell renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Belzutifan(drug)
- Enrollment
- 154 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- Georgetown University Medical Center ( Site 0002), Washington D.C., District of Columbia, United States
- Univ of Miami- Sylvester Comprehensive Cancer Center ( Site 0023), Miami, Florida, United States
- Norton Cancer Institute - St. Matthews ( Site 0025), Louisville, Kentucky, United States
- Weinberg Cancer Institute at Franklin Square ( Site 0007), Baltimore, Maryland, United States
- Cancer Partners of Nebraska ( Site 0003), Lincoln, Nebraska, United States
- Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0012), Omaha, Nebraska, United States
- New York Oncology Hematology P.C ( Site 0028), Albany, New York, United States
- Roswell Park Cancer Institute ( Site 0038), Buffalo, New York, United States
- Fox Chase Cancer Center ( Site 0026), Philadelphia, Pennsylvania, United States
- Sanford Cancer Center Oncology Clinic ( Site 0031), Sioux Falls, South Dakota, United States
- UT West Cancer Center ( Site 0032), Germantown, Tennessee, United States
- Urology Associates ( Site 0015), Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center at Dallas ( Site 0004), Dallas, Texas, United States
- Baylor Scott & White Medical Center - Temple ( Site 0013), Temple, Texas, United States
- Huntsman Cancer Institute ( Site 0037), Salt Lake City, Utah, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04489771 on ClinicalTrials.govOther trials for Hereditary clear cell renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07293351A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07401875A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)M.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07489534Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal DysfunctionDaihong Liu
- ENROLLING BY INVITATIONNANCT06945640Evaluation of 'RUS NE' in Robot-Assisted Partial Nephrectomy: Efficacy, Safety, and StabilityHutom Corp
- RECRUITINGPHASE2NCT07229040A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.Hospital General Universitario Gregorio Marañon
- RECRUITINGNCT07303725Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional OncologyPalo Alto Veterans Institute for Research
- RECRUITINGNANCT07367750Testing the Feasibility of a Self-Management Support Program for Patient With Chronic Diseases in IsraelUniversity of Haifa
- RECRUITINGPHASE1NCT06623630Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal FunctionWashington University School of Medicine
See all trials for Hereditary clear cell renal cell carcinoma →